Andrew Nixon

Professor in Medicine
Andrew Nixon
Andrew Nixon

Overview

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Positions

Professor in Medicine in the School of Medicine

2021 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

1998 School of Medicine

Education

Ph.D. 1997

1997 Wake Forest University

M.B.A. 2007

2007 Duke University

Publications, Grants & Awards

DCI Centers, Cancer Types & Labs

Offices & Contact

133 Jones, Research Drive
Durham, NC
27710
Duke Box 2631
Durham, NC
27710